Neuraxis
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Indiana, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11550 N Meridian St Ste 325, Carmel, Ind...Phone Number
(812) 689-0791Website
www.neuraxis.comRevenue
$5.3 MillionStock Symbol
NRXSIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Neuraxis
NeurAxis is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating condition in children. They are headquartered in Carmel, Indiana. Founded in 2011.Explore more
Neuraxis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neuraxis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Neuraxis launches new products
Earning: See what the market has to say on Neuraxis recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Neuraxis has recently received funding, and reach out quickly before it becomes old news!
Neuraxis, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Neuraxis had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Neuraxis
Funding: Get notified immidiatlly once Neuraxis has new funding data
Check out if Neuraxis is spiking on competitors!
Recommended Actions
Find VP level buyers at Neuraxis
Find 2 more new buyers
Compare Similar Companies to Neuraxis
Compare insights from companies similar to Neuraxis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Neuraxis
$5.3M
11-50
Public
$9.6M
2011
AM
Adrian MirandaSenior VP, Science & Chief Medical Officer, Technology
Company Profile Activity
Activity Insights
Neuraxis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Neuraxis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Neuraxis.
Neuraxis financials insights
Gather financial insights about Neuraxis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Stock Offering
$6.6M
Stock Offering
$3M
Neuraxis Tech Stack
A closer look at the technologies used by Neuraxis
Most Recent Scoops
Project
Neuraxis has announced that its device is placed for four consecutive weeks, with each device costing about $1,200, for a total cost per patient of about $4,800-$5,000. The company has 16 current publications utilizing its technology, including two randomized control trials, all investigator-initiated research.
Product Development, Medical Research, Healthcare Technology
Project
offers a non-pharmacological alternative for children with DGBIs, addressing the lack of FDA-approved therapies prior to IV stem for these conditions. The company's solution responds to the growing demand from families and providers seeking alternatives to drugs with FDA black box warnings and serious side effects.
Product Development, Medical Research, Healthcare Technology
Project
currently has 17 insurance plans covering 51 million lives, with its Category 1 code becoming effective January 1st, 2026. The company has significant IP in place in the United States, with both method and device patents running through 2039, and international IP in process.
Intellectual Property, Legal Affairs, Healthcare Technology
Project
Neuraxis has secured a Category 1 CPT code with RVUs and has increased its PE and FS policy coverage nationally to 51 million covered lives. The company expects these covered lives to reach 100 million or more by the end of December.
Healthcare Technology
Project
Healthcare Technology, Medical Administration
Neuraxis News & Media
NeurAxis Expands Payer Coverage with New Policies
CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-ANeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026
CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its second quarter period ended June 30, 2026, on Tuesday, August 11, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 11, 2026, at 9:00 am ENeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026
CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its second quarter period ended June 30, 2026, on Tuesday, August 11, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 11, 2026, at 9:00 am ENeurAxis (NRXS) Climbs on Reimbursement and Guideline Momentum
Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund” Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund declined by 2.7% in the first quarter of 2026 due to a sharp macro-driven sector rotation following geopolitical tensions, which triggered inflation fears and rising interest rate […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neuraxis
Sign Up For FreeTo access detailed company insights
NeurAxis is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating condition in children. They are headquartered in Carmel, Indiana. Founded in 2011.... Read More
